Comparison 13. IFN‐α + acitretin versus IFN‐α + PUVA.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
13.1 Common adverse effects	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
13.1.1 Grade I to II adverse events	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
13.1.2 Grade III adverse events	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
13.1.3 Adverse events requiring treatment discontinuation	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
13.1.4 Flu‐like symptoms	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
13.1.5 Dryness/redness of skin or hair loss	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
13.1.6 Neurological disorders	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
13.1.7 Psychiatric disorders	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
13.1.8 Gastrointestinal disorders	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
13.1.9 Elevated liver or biliary tract enzymes	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
13.1.10 Elevated triglycerides	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
13.1.11 Anemia	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
13.1.12 Leukopenia	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
13.1.13 Impotentia	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
13.1.14 Redness and infiltration at application site	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
13.2 Complete response	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only